Micelle-Formulated Juglone Effectively Targets Pancreatic Cancer and Remodels the Tumor Microenvironment
Authors:
- Vidhi M. ShahVSVidhi M. Shah
- Syed RizviSRSyed Rizvi
- Alexander SmithASAlexander Smith
- Motoyuki TsudaMTMotoyuki Tsuda
- Madeline KriegerMKMadeline Krieger
- Carl PelzCPCarl Pelz
- Kevin MacPhersonKMKevin MacPherson
- Jenny EngJEJenny Eng
- Koei ChinKCKoei Chin
- Michael W. MunksMMMichael W. Munks
- Colin J. DanielCDColin J. Daniel
- Adel Al-FateaseAdel Al-Fatease
Open Access
- 21 November 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (12) , 2651
Abstract
Pancreatic cancer remains a formidable challenge due to limited treatment options and its aggressive nature. In recent years, the naturally occurring anticancer compound juglone has emerged as a potential therapeutic candidate, showing promising results in inhibiting tumor growth and inducing cancer cell apoptosis. However, concerns over its toxicity have hampered juglone’s clinical application. To address this issue, we have explored the use of polymeric micelles as a delivery system for juglone in pancreatic cancer treatment. These micelles, formulated using Poloxamer 407 and D-α-Tocopherol polyethylene glycol 1000 succinate, offer an innovative solution to enhance juglone’s therapeutic potential while minimizing toxicity. In-vitro studies have demonstrated that micelle-formulated juglone (JM) effectively decreases proliferation and migration and increases apoptosis in pancreatic cancer cell lines. Importantly, in-vivo, JM exhibited no toxicity, allowing for increased dosing frequency compared to free drug administration. In mice, JM significantly reduced tumor growth in subcutaneous xenograft and orthotopic pancreatic cancer models. Beyond its direct antitumor effects, JM treatment also influenced the tumor microenvironment. In immunocompetent mice, JM increased immune cell infiltration and decreased stromal deposition and activation markers, suggesting an immunomodulatory role. To understand JM’s mechanism of action, we conducted RNA sequencing and subsequent differential expression analysis on tumors that were treated with JM. The administration of JM treatment reduced the expression levels of the oncogenic protein MYC, thereby emphasizing its potential as a focused, therapeutic intervention. In conclusion, the polymeric micelles-mediated delivery of juglone holds excellent promise in pancreatic cancer therapy. This approach offers improved drug delivery, reduced toxicity, and enhanced therapeutic efficacy.Keywords
Funding Information
- Brenden-Colson Center for Pancreatic Care (U01CA224012, R01 CA186241, DoD PA210068)
- Brenden-Colson Center Foundation and Oregon State University College of Pharmacy (U01CA224012, R01 CA186241, DoD PA210068)
This publication has 56 references indexed in Scilit:
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013
- Anticancer activity and mechanism of juglone on human cervical carcinoma HeLa cellsCanadian Journal of Physiology and Pharmacology, 2012
- Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on sizeNature Nanotechnology, 2011
- Evaluation of Pharmacokinetic, Biodistribution, Pharmacodynamic, and Toxicity Profile of Free Juglone and Its Sterically Stabilized LiposomesJournal of Pharmaceutical Sciences, 2011
- Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: Formulation, optimization and in vitro characterizationInternational Journal of Pharmaceutics, 2009
- Natural products in drug discoveryDrug Discovery Today, 2008
- Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiersJournal of Controlled Release, 2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Pluronic® block copolymers as modulators of drug efflux transporter activity in the blood–brain barrierAdvanced Drug Delivery Reviews, 2003
- Antineoplastic agents from natural sources: achievements and future directionsExpert Opinion on Investigational Drugs, 2000